Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
QuintilesIMS
Baxter
Julphar
Mallinckrodt
US Army
Johnson and Johnson
McKesson
McKinsey

Generated: April 25, 2018

DrugPatentWatch Database Preview

EMSAM Drug Profile

« Back to Dashboard

When do Emsam patents expire, and what generic alternatives are available?

Emsam is a drug marketed by Somerset and is included in one NDA. There are three patents protecting this drug.

This drug has three patent family members in two countries.

The generic ingredient in EMSAM is selegiline. There are seventeen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the selegiline profile page.
Summary for EMSAM
Drug patent expirations by year for EMSAM
Medical Subject Heading (MeSH) Categories for EMSAM
Synonyms for EMSAM
(-)-(N)-Methyl-N-((1R)-1-methyl-2-phenylethyl)prop-2-yn-1-amine
(-)-Deprenil
(-)-deprenyl
(-)-selegiline
(2R)-N-methyl-1-phenyl-N-prop-2-ynylpropan-2-amine
(r)-(-)-deprenyl
(R)-(-)-N-Methyl-N-(1-phenyl-2-propyl)-2-propinylamin
(r)-(-)-n,2-dimethyl-n-2-propynylphenethylamine
(R)-(-)-N,alpha-Dimethyl-N-2-propinylphenethylamine
(R)-N-Methyl-N-(1-phenylpropan-2-yl)prop-2-yn-1-amine
(r)-selegiline
14611-51-9
14611-52-0 (hydrochloride)
2079-54-1 (deprenyl.hydrochloride)
2K1V7GP655
AC1L1BTZ
AC1Q2860
AJ-74093
AK312654
AKOS000281115
Anipryl
API0009080
Apo-Selegiline
BDBM15579
Benzeneethanamine, N,alpha-dimethyl-N-2-propynyl-, (R)-
Benzeneethanamine, N,alpha-methyl-N-2-propynyl-, (alphaR)-
BPBio1_000687
BRD-K86434416-001-02-7
BRD-K86434416-003-03-1
BSPBio_000623
BSPBio_001589
C07245
Carbex
CHEBI:9086
CHEMBL972
D03731
D0S2UG
D0VC5L
DB01037
DTXSID6023575
Eldepryl
Emsam (TN)
FT-0688371
Gen-Selegiline
GTPL6639
HMS1791P11
HMS1989P11
HMS2089D09
HMS3402P11
Jumex
L-Deprenalin
L-Deprenyl
l-E 250
LS-30156
methyl(1-phenylpropan-2-yl)(prop-2-yn-1-yl)amine
methyl[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-ylamine
MEZLKOACVSPNER-GFCCVEGCSA-N
N-methyl-N-[(1R)-1-methyl-2-phenylethyl]prop-2-yn-1-amine
N-methyl-N-[(2R)-1-phenylpropan-2-yl]prop-2-yn-1-amine
NCGC00024994-01
NCGC00024994-02
NCGC00024994-03
NCGC00024994-04
Novo-Selegiline
Nu-Selegiline
Otrasel
Prestwick0_000552
Prestwick1_000552
Prestwick2_000552
Prestwick3_000552
R(-)-Selegiline solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
SCHEMBL22232
Sd Deprenyl
Selegeline Hcl
Selegene
Selegilina
Selegilina [INN-Spanish]
selegiline
Selegiline (transdermal, Parkinson's/depression)
Selegiline (USAN/INN)
Selegiline [INN:BAN]
Selegiline Hcl
Selegiline Transdermal System (STS) patch
Selegiline, (R)-Isomer
Selegilinum
Selegilinum [INN-Latin]
selegina
Selegyline
selgene
SPBio_002544
STK640578
UNII-2K1V7GP655
UNII-DPF682Q08V component MEZLKOACVSPNER-GFCCVEGCSA-N
US8633208, Deprenyl
Yumex
Zelapar
ZINC19632633
Zunrisa/Rezonic

US Patents and Regulatory Information for EMSAM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-001 Feb 27, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-003 Feb 27, 2006 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-002 Feb 27, 2006 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-003 Feb 27, 2006 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for EMSAM

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-003 Feb 27, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-002 Feb 27, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Somerset EMSAM selegiline FILM, EXTENDED RELEASE;TRANSDERMAL 021336-001 Feb 27, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for EMSAM

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,846,093 Adhesive mixture for transdermal delivery of highly plasticizing drugs ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
US Department of Justice
Merck
Fish and Richardson
Daiichi Sankyo
Teva
Cantor Fitzgerald
Cipla
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.